NVAX Stock Overview
A biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Novavax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.28 |
| 52 Week High | US$13.35 |
| 52 Week Low | US$9.14 |
| Beta | 2.03 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -14.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| NVAX | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | -21.3% | 1.7% | 0.6% |
| 1Y | n/a | 5.1% | 7.6% |
Return vs Industry: Insufficient data to determine how NVAX performed against the Austrian Biotechs industry.
Return vs Market: Insufficient data to determine how NVAX performed against the Austrian Market.
Price Volatility
| NVAX volatility | |
|---|---|
| NVAX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in AT Market | 6.2% |
| 10% least volatile stocks in AT Market | 1.9% |
Stable Share Price: NVAX's share price has been volatile over the past 3 months compared to the Austrian market.
Volatility Over Time: Insufficient data to determine NVAX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,543 | John Jacobs | www.novavax.com |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
Novavax, Inc. Fundamentals Summary
| NVAX fundamental statistics | |
|---|---|
| Market cap | €1.50b |
| Earnings (TTM) | -€271.82m |
| Revenue (TTM) | €912.11m |
1.7x
P/S Ratio-5.6x
P/E RatioIs NVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVAX income statement (TTM) | |
|---|---|
| Revenue | US$987.67m |
| Cost of Revenue | US$827.91m |
| Gross Profit | US$159.76m |
| Other Expenses | US$454.09m |
| Earnings | -US$294.33m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.84 |
| Gross Margin | 16.18% |
| Net Profit Margin | -29.80% |
| Debt/Equity Ratio | -39.1% |
How did NVAX perform over the long term?
See historical performance and comparison